Gliptinaid M 500 Tablet ER is a combination oral antidiabetic medication containing Metformin 500 mg and Teneligliptin 20 mg, formulated for extended release to provide sustained glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide class agent, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances endogenous incretin hormone levels, thereby increasing insulin secretion and suppressing glucagon release in a glucose-dependent manner. The extended-release formulation ensures a gradual and consistent plasma concentration, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Gliptinaid M 500 Tablet ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly when monotherapy with metformin or DPP-4 inhibitors is insufficient. It should be used with caution in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose levels, renal function, and potential adverse effects is recommended. This combination therapy offers a complementary mechanism of action, targeting multiple pathophysiological defects in type 2 diabetes for optimal glycemic management.